TRIAL FOR THE EVALUATION OF THE EFFECT OF SYSTEMIC LOW-DOSE INTERLEUKIN-2 (IL-2) ON THE IMMUNOGENICITY OF A VACCINE COMPRISING SYNTHETIC MELANOMA PEPTIDES ADMINISTERED WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF)-IN-ADJUVANT, IN PATIENTS WITH HIGH RISK MELANOMA: